Novo Nordisk's pricing strategies from the U.S. have drawn sharp criticism from lawmakers like Senator Sanders, who has accused the company of value gouging, stating the stark contrast among U.S. selling prices and people in Europe and copyright. are scheduled to get operation or other pr